Mortality was studied in 14 111 patients with ankylosing spondylitis given a single course of x-ray treatment during 1935-54. Mortality from all causes combined was 66% greater than that of members of the general population of England and Wales. There were substantial excesses of deaths from non-neoplastic conditions, but these appeared to be associated with the disease itself rather than its treatment. A nearly fivefold excess of deaths from leukaemia and a 62% excess of deaths from cancers of sites that would have been in the radiation fields ("heavily irradiated sites") were likely to have been a direct consequence of the radiation treatment itself. The excess death rate from leukaemia was greatest three to five years after treatment and was close to zero after 18 years. In contrast, the excess of cancers of heavily irradiated sites did not become apparent until nine or more years after irradiation and continued for a further 11 years. More than 20 years after irradiation the excess risk declined, but the fall was not statistically significant. The number of cancers of sites not considered to be in the radiation beams was 20% greater than expected. This excess, although not statistically significant, may also have been due to radiation scattered from beams directed at other parts of the body.
Mortality was studied in 14 111 patients with ankylosing spondylitis given a single course of x-ray treatment during 1935-54. Mortality from all causes combined was 66% greater than that of members of the general population of England and Wales. There were substantial excesses of deaths from non-neoplastic conditions, but these appeared to be associated with the disease itself rather than its treatment. A nearly fivefold excess of deaths from leukaemia and a 62% excess of deaths from cancers of sites that would have been in the radiation fields ("heavily irradiated sites") were likely to have been a direct consequence of the radiation treatment itself. The excess death rate from leukaemia was greatest three to five years after treatment and was close to zero after 18 years. In contrast, the excess of cancers of heavily irradiated sites did not become apparent until nine or more years after irradiation and continued for a further 11 years. More than 20 years after irradiation the excess risk declined, but the fall was not statistically significant. The number of cancers of sites not considered to be in the radiation beams was 20% greater than expected. This excess, although not statistically significant, may also have been due to radiation scattered from beams directed at other parts of the body.
The risk of a radiation-induced leukaemia or other -cancer was related to the age of the patient at the time of treatment. Those irradiated when aged 55 years or more had an excess death rate from leukaemia more than 15 times that of those treated under 25 years of age, and a similar difference was apparent for cancers of heavily irradiated sites. The radiation dose to the bone marrow was estimated for the patients who died with leukaemia Introduction Court Brown and Doll identified over 14 000 patients with ankylosing spondylitis who had been treated with one or more courses of x Irradiation from 1935 to 1954 at one of 87 radiotherapy centres in Great Britain and Northern Ireland. Previous reports have analysed mortality among these patients from leukaemial and other causes, particularly cancer2 but these analyses included many patients who had been treated with x rays for their spondylitis more than once. This complicated the interpretation of the late effects of the treatment on mortality as it was not clear to what extent the subsequent treatments contributed to the excess of deaths that persisted for many years after the first treatment. We have avoided this difficulty by examining the death rate from leukaemia and other radiationinduced cancers at different times after a single course of treatment.
Methods

STUDY POPULATION AND FOLLOW-UP
A total of 14 560* patients were included in the study (table I) . Of these we excluded 406 who were entered into the study at the date of * 14 554 patients were included in the previous report.2 One patient was found to have been included twice and seven to have been omitted from the previous analysis. their second or later radiation treatment course and 43 whose date of birth or age at first treatment was unknown. All except 208 (1 5%) of the remaining 14 111 patients were traced to their death, date of emigration from the United Kingdom, 1 January 1970, or the end of the year after their second treatment course, whichever was the earliest. Retreated patients were traced for on average 18 months beyond their second course (to the end of the year after the one in which they were retreated). Any leukaemias or cancers induced by the second course of radiation treatment were unlikely to have appeared and caused death in this short interval. Some patients may, however, have received a second course as a result of the early symptoms of a cancer being misdiagnosed as reactivated spondylitis and treated accordingly, and failure to have followed them beyond the date of the second treatment course might have led us to underestimate the number of radiation-induced tumours associated with the original radiation treatment.
Over half of the patients were retreated before 1 January 1970, 1759 patients had died, and 269 had emigrated. The remaining 4420, who received only one course of treatment, were alive and living in the United Kingdom on 1 January 1970 (table I). The average follow-up BRITISH MEDICAL JOURNAL VOLUME 284 13 FEBRUARY 1982 months. The numbers of deaths expected by cause were estimated by multiplying the person-years at risk by the corresponding age-and sex-specific mortality rates for England and Wales. Cancer death rates were taken from the tables published by Case et a14 and by the Office of Population Censuses and Surveys,5 and death rates for other causes were compiled from the annual reports of the Registrar General for England and Wales. All death rates were based on the 7th revision of the ICD. For years in which the Registrar General had used revisions other than the 7th the equivalent classifications were calculated from the published data. The number of years at risk were calculated separately for men and women for each five-year age group and for 193540, for each quinquennium from 1941-5 to 1961-5, and for 1966-9. Differences between the actual number of deaths from each cause and the number expected were tested for statistical significance by calculating the probability of obtaining a value greater than or equal to the number observed if sampling from a Poisson distribution with a mean equal to the expected number of deaths-that is, one-sided tests were performed. Tests for trends were performed using the method described by Mantel6 and were two-sided tests. For the 1957 report, estimates of the mean radiation dose to the spinal bone marrow and of the whole body integral dose were derived for a sample of approximately one in six of the patients in the original series. The sample of one in six patients was selected separately for each centre for each year in which treatment was started, and different sampling fractions were used for each of the five "amount of treatment" classes. The allocation of a patient to a class depended on whether he or she had had 1, 2, 3, 4 or more courses of treatment (classes 1 to 4) or had been treated at two or more centres (class 5). For patients receiving only one treatment course a 1 in 15 sample was selected, but larger sampling fractions were used in the groups receiving two or more courses of radiation as there were fewer patients in these groups and the more heavily treated patients were of greatest interest. In the 1957 report1 radiation doses from different treatment courses were added together to derive an overall dose for each sampled patient. In this analysis we were concerned only with the dose from the first or only course of treatment. There was no reason to emphasise the dosage estimation for patients treated more than once, so we selected patients at random, within each treatment centre, from the patients who had been included in sampling classes 2 to 5, so as to obtain a 1 in 15 sample of patients from each class. The numbers of patients included in the final sample from each class are shown in table II.
For each sampled patient information was sought from the radiotherapy notes on the size and location of each radiation field used in the first course of treatment, the skin dose of radiation to each field, the focal skin distance used, the filtration used, and the voltage of the x-ray machine. From these data we derived an estimate, for each sampled patient, of the mean radiation dose to the bone marrow using a computer program which incorporated the results of extensive dose measurements on a phantom.7
Of the 963 patients in the sample (table II) 28 were excluded because either their date of birth was not known (three patients) or they had entered the study having had previous treatment for ankylosing spondylitis. Both of these categories of patients had already been excluded from the main study. (table III) . This 66% excess of deaths was statistically highly significant, as was the excess from all neoplasms and from all other causes (in each case p<0 001). The size of these excesses was similar in men and women, and the differences in the ratios of observed to expected deaths between the sexes were not statistically significant. Women made up only 16500 of the study population and, as the findings among women were similar to those for men, the two sexes were considered together in most of the subsequent analyses.
Neoplastic diseases
Following the procedure adopted by Court Brown and the leukaemia is thought to have been the cause of the symptoms which led to the treatment.1 These deaths were excluded from subsequent analyses, and the expected number of deaths from leukaemia were computed from, on average, 18 months after first treatmentthat is, from the beginning of the second year after the year of first treatment (no deaths from leukaemia occurred in the year after the year of first treatment). The case notes were reviewed for the four patients in the series whose cause of death was given on their death certificate as aplastic anaemia,' and for two (who died at two and four years after first treatment for spondylitis) it was considered that death was actually due to leukaemia. Leukaemia was also recorded on the death certificate, though not as the underlying cause of death, for five other patients (who died at 5, 6, 10, 12, and 16 years after first treatment). The lower section of table V shows the estimated excess death rates with leukaemia when these additional seven patients were included. No data for the study period were available for deaths in England and Wales as a whole with leukaemia mentioned on the death certificate but not as the underlying cause of death, nor was there information on the number of deaths from leukaemia that were certified as due to aplastic anaemia. We assumed that the ratio of the number of such deaths to the number of deaths for which leukaemia was certified as the underlying cause was the same as we observed in our study series. Thus to estimate the number of deaths with leukaemia that would have been expected based on England and Wales mortality rates (including those for which leukaemia was not the certified cause)
we multiplied the expected numbers based on the underlying cause (table IV) by 35/28-that is, the total number of deaths with leukaemia in the study series two or more years after first treatment divided by the number for which leukaemia was certified as the underlying cause. The revised expected numbers are shown in the lower section of table V. In the period from the second year after first treatment the excess death rate with leukaemia was estimated to be 24 5 per 100 000 person-years at risk.
Cancer of the colon-The ratio of observed to expected deaths from cancer of the colon, 1 62:1 (table III; p < 0 05), was similar to that for cancers of the heavily irradiated sites (1 55 :1). The ratio was highest in the period immediately after the first treatment course, with six deaths in the 18 months immediately after radiotherapy (table IV) . Subsequently there was still a statistically significant excess (p = 005), but within this period there was no significant change in the ratio of observed to expected deaths with time since entry to the study.
Cancers of lightly irradiated sites-There was a 20% excess of deaths from cancers of sites that were considered to be lightly irradiated, but this was not quite statistically significant (table III; p --0-06). There was no significant change in the ratio of observed to expected deaths with time since first treatment (table IV) . The observed and expected deaths associated with the individual sites that were classified as "lightly irradiated" are shown in table VI, divided according to whether they occurred in the first two years after radiotherapy or later. (The reasons for considering separately the first two years after radiotherapy are discussed in the next section.) Three or more years after first treatment there were excess numbers of deaths from cancers of several sites, but in no case was the excess statistically significant, nor was the variation in the ratio of observed to expected deaths for each site. The only significant excess of deaths in the first two years after treatment was for cancer of the prostate, with three deaths against 0-7 expected (p < 0 05). Two of these occurred in the same year as the first treatment for spondylitis and may have caused the symptoms that were attributed to spondylitis.
Cancers of heavily irradiated sites-There was a 55°excess of cancers of sites judged to be directly in the radiation beams, a statistically highly significant excess ( BRITISH MEDICAL JOURNAL VOLUME 284 13 FEBRUARY 1982 patients with spondylitis. In fact, however, they were also in excess in patients with spondylitis,2 IO and this was confirmed by our data, based on a longer period of follow-up. The relative excesses, however, were less than those for diseases in classes A and B (other than amyloid disease). The findings for the different causes of death were similar in both sexes (table VIII) . Overall there was a 690°excess of deaths from causes other than neoplasms, and the ratio of observed to expected deaths from these causes remained approximately constant at different times after irradiation (table IV) .
EFFECT OF AGE AT FIRST TREATMENT
Cancers of heavily irradiated sites
In table IX the numbers of observed and expected deaths from cancers of heavily irradiated sites occurring three or more years after first treatment were divided into five groups according to the age of the patient when first treated. The results provide no evidence of any change in the ratio with age (X2 (1 df trend)= 0-74; p > 0 20). Excess death rates, however, increased rapidly with increasing age at first treatment (X2 (1 df trend)=14-94; p<0001). Among patients first treated at the age of 55 years or more the excess death rate from cancers Table XI shows the change in risk of death from leukaemia two or more years after first treatment according to the age of the patients when treated. There was a statistically significant increase in the excess death rate from leukaemia among patients first irradiated at an old age (^2 (1 df trend)=6-73; p<001) but no evidence of any appreciable change in the ratio of observed to expected deaths with age at first treatment (;1 (1 df trend) 0-03; p > 0-80).
EXCESS MORTALITY RELATED TO RADIATION DOSE
Leukaemia
The estimated mean bone marrow radiation dose associated with the first course of treatment among the 903 patients for whom full data on radiation treatment were extracted from radiotherapy records (table II) was 321 rads. (There was a higher proportion of patients with insufficient data for dose estimation in sampling classes 4 and 5 than in sampling classes 1 to 3 (table 2). As patients in sampling class 4 for whom a dose estimate was made had a lower mean dose than those in sampling class 1, the exclusion of patients with insufficient data probably overestimated the mean dose to the whole group. If we assume, however, that patients with insufficient data received, on average, the same dose as those in the same sampling class for whom sufficient data were available, we estimate that the mean dose to the whole population was 319-9 rads, which is close to that obtained when the patients with insufficient data were ignored (320 8 rads). In subsequent computations only the patients with estimated doses were Numbers in parentheses include 7 deaths for which leukaemia was not the primary cause but for which leukaemia was the preferred diagnosis or was mentioned on the death certificate. 
Causes other than neoplasms
For all causes other than leukaemia or other cancers the ratio of total observed to expected deaths was highest among those first treated under the age of 25 years and lowest among those first treated at age 55 years or above (table XI). The decline in the value of the ratio with age at treatment was highly significant (X21 (trend)=38-3; p<0 001). Conversely, however, the excess death rate increased with increasing age at first treatment (though much less rapidly than the excess death rate from cancers of heavily irradiated sites), and this trend was also highly significant (X21 (trend) =54-3; p< 001). 
Cancers other than leukaemia
The average radiation doses received by 10 organs, as estimated by the BEIR committee,9 are shown in table XIV. We related the doses to the excess mortality observed from cancers of these sites in the periods three or more years after irradiation and nine or more years after irradiation. The latter period was used as there was little evidence of any increased risk from cancer (except leukaemia) during the first eight years after treatment. Following the BEIR Committee9 we related the excess of lymphomas other than Hodgkin's disease to the 
Discussion
Previous analyses of the mortality among patients with ankylosing spondylitis treated with x rays' 2 included deaths among patients who had received more than one course of x ray treatment. This made it difficult to measure the size of changes associated with either the dose of radiation or the length of time since the radiation exposure because it was not obvious how to take into account the effects of the second or subsequent course of radiation on the death rates. We avoided the problem in this 457 exposure rather than to the underlying disease. They do not support the suggestion that radiation exposure produces a nonspecific "aging" effect, affecting death rates from causes other than cancer (except possibly aplastic anaemia). We have discussed elsewhere the increase in mortality associated with spondylitis itself10 and confine the discussion here to deaths from leukaemia and other cancers.
LEUKAEMIA
There is overwhelming evidence that ionising radiations are leukaemogenic in man." What is less certain is the way in which the risk of developing leukaemia varies with time after radiation exposure, the dose of radiation, and the age and other characteristics of the person irradiated. In this study the risk of dying of leukaemia was raised by the second year after treatment and the greatest risk was 3 to 5 years after treatment. Subsequently both the ratio of observed to expected deaths and the excess death rate declined significantly. Only five deaths occurred from 12 to 17 years after first treatment (1 9 were expected), and there was only (table IV) . A smaller group of patients with ankylosing spondylitis, who were diagnosed during the same period as patients in this series but who were not treaed with x rays also had mortality rates which were about 60% greater than expected from national rates, and this strongly suggests that the x ray treatment is responsible for inducing a relatively small proportion of the total excess of deaths in irradiated patients."0 12 When deaths were examined separately by cause, no deaths from leukaemia were observed in patients who had not been irradiated and the number of deaths from cancers of sites that would have been classed as "heavily irradiated" in the patients treated with x rays was close to the number expected. In contrast the ratio of the number of deaths from non-neoplastic conditions to the number expected (1-8:1) was close to that in the irradiated patients (table III: 1-7:1). These findings must be interpreted with caution as the number of patients who had not been treated with x rays was comparatively small (1021) and the percentage of those patients who were not completely traced to the end of the study period (16%) was undesirably high. The results indicate, however, that the excess of deaths from leukaemia and cancers of the heavily irradiated sites among irradiated patients are likely to be due to the radiation one death from leukaemia 18 or more years after first treatment when one was expected (table IV) . When the excess risk of leukaemia was standardised for age at first treatment the results were barely changed (table XII). Our data were too sparse to rule out the possibility that no excess risk remains beyond 18 years after exposure, but most of the radiation-induced leukaemias have probably already occurred. A similar finding has been reported for the survivors of the atomic bomb explosions. The excess risk of leukaemia was considerably reduced by 20 years after the explosions but some remained beyond this period." 14 Two or more years after treatment the overall excess mortality from leukaemia was 19-6/100 000 person years at risk, or 24 5/100 000 person years at risk when we included the seven patients with leukaemia whose primary cause of death was not given as leukaemia on their death certificates.
To use these rates to estimate the leukaemogenic effects of radiation on populations exposed to different levels of radiation it is necessary to relate the excess risk to the estimated mean bone marrow dose and, as illustrated by fig 2, the assumption of a linear dose-response relationship over the whole range of doses received by the spondylitic patients may not be justified.
Patients irradiated for the treatment of cervical cancer do not appear to have an increased risk of leukaemia"5 16 whereas women given a radiation-induced menopause have shown an increased death rate from leukaemialI even though their bone marrow is likely to have received a much smaller dose of radiation. These observations are incompatible with a linear dose-response relationship for leukaemia induction by radiation."5 18 It has been suggested that patients with cancer of the cervix are not at increased risk of leukaemia because the radiation treatment is given in such a way that some of the bone marrow receives a very high dose of radiation, sufficient to sterilise the marrow cells, and that the dose to the rest of the marrow falls off rapidly with increasing distance from the cervix. Thus, most of the marrow cells receive either a radiation dose which is so damaging that they cannot survive a division or a dose which is so small that it confers too small a risk of leukaemia to be detectable in epidemiological studies.
Many of the spondylitic patients in our study received an estimated mean marrow dose of over 300 rads. As only part of the marrow is irradiated in the treatment of spondylitis, the dose to cells directly in the radiation field may have been higher than the mean dose by a factor of two or more (the spinal marrow constitutes about 40% of the total bone marrow). Thus manyof the cells directly in the line of the radiation may have received a dose large enough to sterilise them and thus render them incapable of becoming leukaemic.
Mathematical models relating the risk of leukaemia to radiation dose that take account of the cell-sterilising effect of radiation fit well with experimental data on radiation-induced myeloid leukaemias in mice,"9 and Mole20 has fitted models of this nature to data from human studies. We have fitted some of these models to the data on leukaemia shown in In comparing our results with those from other studies it should be noted that after first treatment patients have been *withdrawn from our study at a faster rate than might generally be expected. Not only do spondylitics have a considerably raised death rate from other causes, unassociated with the radiation exposure, but for the present analysis they were also withdrawn shortly after their second treatment, which a high proportion of patients received (table I) .
The net result of these two effects was for the distribution of the number of person years at risk according to the time since first treatment to be weighted towards the first few years after treatment, when the risk of a radiation-induced leukaemia is relatively high. Thus the summary risk estimates given previously will be too high for estimating the possible effects of radiation exposure on other populations. We therefore applied the rates given in table XII (after standardisation for age at irradiation) to a standard population with the same age distribution as that of the spondylitics at the time of irradiation to derive estimates of the excess risk of leukaemia in the 20 years after exposure in the absence of other causes of death (we assumed that there was no excess risk of leukaemia in the first 18 months after exposure). We estimated that 318 deaths from leukaemia will be induced per 100 000 persons irradiated-that is, 15 9/100 000 per year.
CANCERS OF LIGHTLY IRRADIATED SITES
We classified body sites into those which were lightly or heavily irradiated taking into account the body areas to which radiation fields were usually applied in the treatment of spondylitis in the patients in this series. This was necessarily a rough division, as treatment practices varied considerably between centres, and some of the sites classed as lightly irradiated may not always have been excluded from the treatment fields. Furthermore, some of these sites probably received some radiation as scatter from treatment applied close by. Thus, although none of the individual sites shown in table VI was associated with a statistically significant increased risk of cancer, the excess of deaths over the expected numbers for cancers of the kidney and bladder may be due in part to radiation effects. The original treatment details were not available for most patients and thus the position of the radiation fields for those patients developing cancer could not be checked. Three or more years after first treatment there was an overall excess of deaths from cancers of lightly irradiated sites of about 20%, but this increase was not statistically significant and was significantly less than the corresponding 50% excess of deaths from cancers of heavily irradiated sites (tables VII and VIII; X2 (1 df)=2-72; p <0 05 (one-sided)).
Estimates were given by the BEIR committee9 of the doses to the kidneys and the bladder and on the basis of these, we estimated that the excess risk of cancers of these sites three or more years after radiation were 0-7 and 1 3/106/persons/year/rad respectively (table XIV).
CANCERS OF HEAVILY IRRADIATED SITES
The ratios of observed to expected deaths three or more years after first treatment for cancers of sites classed as heavily irradiated showed some variation (table VII), but when CNS tumours were excluded (some of which may have been present at the time of first treatment) the variation was not statistically significant. Thus our data were compatible with the radiation risk being directly proportional to the expected death rate from cancer in the absence of radiation. As we also observed for leukaemia, this suggests that radiation interacts in a multiplicative way with other factors which induce cancer. Further evidence is provided by the observation that for patients first irradiated at different ages the subsequent risk of dying of cancer was approximately proportional to the expected cancer death rate in the absence of any radiation treatments (tables IX and X). Nevertheless, all our data related to adults, and children aged less than 10 years may be particularly sensitive to the carcinogenic effects of radiation."4
The ratio of observed to expected deaths from cancers of heavily irradiated sites declined after reaching a peak 9 to 11 years after first treatment (table IV) . The excess death rate, however, remained roughly constant up to 20 years after first treatment (tables V and X) and there was only slight evidence of a fall in this rate with longer periods of observation. Thus, while the risk of leukaemia to the spondylitics would seem to have diminished considerably, if not disappeared, by 20 years after first treatment, the risk of other radiation-induced cancers remains and it will be necessary to continue to follow-up the surviving patients to determine whether the excess cancer risk declines as the time since first treatment increases further.
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